Randomized Double-Blind Trial of Darbepoetin Alfa in Patients With Symptomatic Heart Failure and Anemia | Zendy

Jalal K. Ghali | Zendy; Inder S. Anand | Zendy; William T. Abraham | Zendy; Gregg C. Fonarow | Zendy; Barry Greenberg | Zendy; Henry Krum | Zendy; Barry M. Massie | Zendy; Scott M. Wasserman | Zendy; Marie-Louise Trotman | Zendy; Yan Sun | Zendy; Beat Knüsel | Zendy; Paul W. Armstrong | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Randomized Double-Blind Trial of Darbepoetin Alfa in Patients With Symptomatic Heart Failure and Anemia

Author(s) -

Jalal K. Ghali,

Inder S. Anand,

William T. Abraham,

Gregg C. Fonarow,

Barry Greenberg,

Henry Krum,

Barry M. Massie,

Scott M. Wasserman,

Marie-Louise Trotman,

Yan Sun,

Beat Knüsel,

Paul W. Armstrong

Publication year - 2008

Publication title -

circulation

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 7.795

H-Index - 607

eISSN - 1524-4539

pISSN - 0009-7322

DOI - 10.1161/circulationaha.107.698514

Subject(s) - medicine , darbepoetin alfa , heart failure , randomized controlled trial , double blind , anemia , epoetin alfa , cardiology , placebo , alternative medicine , pathology

Substantial evidence suggests that anemia is an independent risk factor for worse outcomes in patients with heart failure (HF). The Study of Anemia in Heart Failure Trial (STAMINA-HeFT) is the largest multicenter, randomized, double-blind, placebo-controlled trial to date evaluating the effect of treating anemia in HF.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research